Axion BioSystems is pleased to announce the appointment of James Guo as Regional Sales Director, APAC. James brings a wealth of knowledge from his 15 years sales experience in the life science industry. James worked for several years in sales with both Merck and Qiagen. For the past 5 years he has managed sales in the APAC region for Seahorse Bioscience/Agilent.
August has been a busy month for Axion, and you can find out why in the latest edition of the Circuit newsletter. Join us as we celebrate a Maestro Milestone, our customers have passed the one million wells of Maestro MEA data mark! Also, check out the Axion Travel Award and the large selection of neuron-focused Maestro publications this month.
Click here to find out more and start exploring life's circuitry.
The July edition of Axion's Circuit Newsletter is packed with data centered on Maestro-driven neurological research. In this month's Coffee Break Webinar, Dr John Graef (Fulcrum Therapeutics) expands on his recent Cell paper by discussing reversing Fragile X Syndrome phenotypes in a dish using Maestro technology. Additionally, learn how Maestro MEA research is helping to study the infectious ability of the Zika and Dengue viruses using induced pluripotent stem cell-derived glial cells.
Introducing Lumos 24, Axion's award-winning multiwell optical stimulation device now available in a 24-well format. Incorporate cutting-edge optical techniques into your in vitro research using Axion BioSystems’ Lumos.
Lumos 24 offers precise control over intensity and duration of four stimulation wavelengths per well, providing ultimate flexibility for optical assays. Lumos 24 pairs seamlessly with the Maestro Edge multiwell MEA system to simultaneously direct and record functional network activity.
With the release of the CiPA Phase II Myocyte study results, this summer edition of the Axion Circuit newsletter has a focus on the heart. June’s copy features a webinar highlighting Dr. Vincenzo Macri's (STEMCELL Technologies) research on recreating patient heart beats in a dish, and the release of Axion's new LEAP cardiomyocyte assay is discussed in AxIS Tips.
The results from the CiPA Phase II multi-site, blinded validation study are now in. The CiPA team conclusively demonstrated the utility of human stem cell-derived cardiomyocytes to detect drug-induced arrhythmia effects. We are proud that the Maestro MEA system played a pivotal role in the study. We would also like to thank all the Maestro MEA users at big pharma for making us look great.
Congratulations Dr Daniel Millard and the CiPA Myocyte team on the publication of the CiPA Myocyte Pilot Study. A first of its kind, the CiPA Myocyte assay, proposes using beating human stem cell-derived heart cells, known as cardiomyocytes, to identify drugs that promote the irregular beating of the heart.
We are proud that the Maestro MEA system played a pivotal role in the study. Click here to learn more about the CiPA Myocyte Study and the Maestro MEA platform.
Neurological research has changed profoundly since the discovery of human induced pluripotent stem cells (iPSC), ten years ago. New methods to efficiently generate patient-derived neuronal culture provide unprecedented opportunities to gain new insights into a range of neurological and psychiatric disorders. In addition, breakthroughs in genetics and omics analysis are making molecular profiling of neurons much more accessible and thorough.
At Axion BioSystems we understand the need to explore life’s circuitry.
Many neurological disorders are highly debilitating, and the current treatment options are limited to symptom reduction rather than providing a cure. Advances in differentiating iPSCs towards a variety of neural cell types have recently unveiled promising opportunities to understand neurological diseases using patient cells.